title: Systemic and regional free fatty acid metabolism in type 2 diabetes.
abstract: To determine whether type 2 diabetes mellitus alters systemic and regional free fatty acid ([3H]palmitate) metabolism, 14 nondiabetic (ND) and 14 type 2 diabetic (D) subjects underwent hyperinsulinemic-hyperglycemic (approximately 9.3 mM) clamps. The subjects were matched for age, body mass index, percent body fat, and fat-free mass. D subjects had more (P < 0.05) visceral fat than ND. During somatostatin, replacement growth hormone, and glucagon infusions, insulin was infused to achieve moderate (approximately 75 pmol/l) and high (approximately 150 pmol/l) physiological insulin levels. D subjects had greater (P < 0.02) systemic and regional (splanchnic and leg) palmitate release than ND subjects during both insulin infusion intervals. The relative contributions of splanchnic, leg, and nonsplanchnic upper body regions to systemic palmitate release did not differ between groups, although the last contributed the most (approximately 75%) to systemic palmitate release. Visceral fat area correlated with systemic palmitate flux (r = 0.45, P < 0.03) during both insulin infusions. We conclude that type 2 diabetes is associated with a generalized impairment in insulin suppression of lipolysis compared with equally obese ND individuals.
authors.affiliation: Endocrine Research Unit, Division of Endocrinology and Metabolism, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
authors.forename: A
authors.initials: A
authors.lastname: Basu
authors.forename: R
authors.initials: R
authors.lastname: Basu
authors.forename: P
authors.initials: P
authors.lastname: Shah
authors.forename: A
authors.initials: A
authors.lastname: Vella
authors.forename: R A
authors.initials: RA
authors.lastname: Rizza
authors.forename: M D
authors.initials: MD
authors.lastname: Jensen
mesh_terms: D000005:Abdomen; D000273:Adipose Tissue / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005260:Female; D005934:Glucagon; D006728:Hormones; D019382:Human Growth Hormone; D006801:Humans; D006946:Hyperinsulinism / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000097:blood; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008066:Lipolysis / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism; D010168:Palmitates / Q000097:blood; D011500:Protein Synthesis Inhibitors; D013004:Somatostatin; D014316:Tritium
chemical_list: D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D006728:Hormones; D007004:Hypoglycemic Agents; D007328:Insulin; D010168:Palmitates; D011500:Protein Synthesis Inhibitors; D014316:Tritium; D019382:Human Growth Hormone; D013004:Somatostatin; D005934:Glucagon